Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce the addition of Holden Hodgson as Senior Managing Director, Derivatives. Mr. Hodgson will be based in the ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Lexeo Therapeutics in ...

On Monday, Fulcrum Therapeutics Inc (FULC) stock saw a modest uptick, ending the day at $3.03 which represents a slight increase of $0.02 or 0.66% from the prior close of $3.01. The stock opened at $3 ...

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), retaining the price target ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

On Monday, 10X Genomics Inc (TXG) stock saw a decline, ending the day at $13.18 which represents a decrease of $-0.16 or -1.20% from the prior close of $13.34. The stock opened at $13.34 and touched a ...

Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced ...

CVS Health has added four new board members, including the CEO of a hedge fund that has been critical of the struggling ...

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks ...